Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
First Claim
Patent Images
1. A synthetic, modified single-stranded oligonucleotide of 15 to 18 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is(i) an antisense compound which is 100% complementary to and specifically hybridizes to a 15 to 18 nucleotide target region within nucleotides 1-2535 of a natural antisense polynucleotide of a Brain derived neurotrophic factor polynucleotide having SEQ ID NO;
2 and(ii) is specific for said natural antisense polynucleotide and upregulates the function and/or expression of a Brain derived neurotrophic factor (BDNF) gene in vivo or in vitro as compared to a mock-transfected control and wherein there is at least a 1.4 fold average increase in expression over said control.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonecleotides and their use in treating diseases and disorders associated with the expression of BDNF.
-
Citations
15 Claims
-
1. A synthetic, modified single-stranded oligonucleotide of 15 to 18 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is(i) an antisense compound which is 100% complementary to and specifically hybridizes to a 15 to 18 nucleotide target region within nucleotides 1-2535 of a natural antisense polynucleotide of a Brain derived neurotrophic factor polynucleotide having SEQ ID NO;
2 and(ii) is specific for said natural antisense polynucleotide and upregulates the function and/or expression of a Brain derived neurotrophic factor (BDNF) gene in vivo or in vitro as compared to a mock-transfected control and wherein there is at least a 1.4 fold average increase in expression over said control. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- at least one modified sugar moiety;
Specification